International Journal of Breast Cancer · 2014 · 10 citations · 12 references
MedicineOncologyPathologyBreast OncologyCancer EpidemiologyMolecular OncologyBreast PathologyHer2-positive Breast CancerMalignant NeoplasmsMammary TumorsBreast Cancer Molecular SubtypesHer2 AmplificationHer2 ExpressionHer2 Gene AmplificationHuman Epidermal Growth Factor Receptor 2 (Her2) ExpressionNuclear Hormone ReceptorsP53 MutationPathologic Classification
Prognostic factors are in interest for breast cancer as the second cause of malignancy deaths. Some have predictive values as human epidermal growth factor receptor-2 (HER-2) and estrogen receptor (ER). To access the incidence of HER2 and its relations to other factors, like age, pathology, ER, progesterone receptor (PR), and P53, 2000 pathologic blocks from 2750 total samples have been selected from 2011 to 2013 in Cancer Institute of Tehran. Incidence of HER2, ER, PR, and P53 was; 58.5%, 33.4%, 43.3%, and 65.4%, respectively. Invasive ductal carcinoma was the most pathologic type (82.2%) and 60%-70% positive HER2 and P53 had negative ER and PR (poor prognosis). The peak age of incidence of breast cancer was perimenopausal age group (46-55 years). Our cases had more positive HER2 and P53 and less positive PR and ER compared to other studies. High perimenopausal incidence as another finding assures the importance of breast cancer screening in these age groups.
12
Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer
Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.9K citations
Timothy W. Jacobs, Allen M. Gown, Hadi Yaziji et al. · Journal of Clinical Oncology · 1999 · 459 citations · Full text
Chromogenic in Situ Hybridization
Minna Tanner, David Gancberg, Angelo Di Leo et al. · American Journal Of Pathology · 2000 · 378 citations · Full text
Medicine, Cancer Biology, Oncology +15